Amgen Inc (AMGN.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|56||2013||Chairman of the Board, President, Chief Executive Officer|
|62||2014||Executive Vice President, Chief Financial Officer|
|52||2018||Executive Vice President of Global Commercial Operations|
|56||2018||Executive Vice President - Research and Development|
|51||2016||Executive Vice President, Operations|
- UPDATE 1-U.S. drugmakers file lawsuit against requiring drug prices in TV ads
- U.S. drugmakers file lawsuit against rule requiring drug prices in TV ads
- Swiss stocks - Factors to watch on June 14
- BRIEF-Amgen Wins FDA Approval For Kanjinti Injection For Treatment Of Breast Cancer, Gastroesophageal Junction Adenocarcinoma - FDA
- FDA approves Lilly's migraine drug as first ever cluster headache treatment